Introduction {#s1}
============

Cutaneous melanomas can vary significantly in their clinical and histopathological appearance, which has lead to the development and refinement of morphologically based classification systems. The current World Health Organization (WHO) classification of skin tumors \[[@pmed-0050120-b001]\], which is an extension of the revised Sydney classification from 1986 \[[@pmed-0050120-b002]--[@pmed-0050120-b004]\], distinguishes four main types of melanoma; superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), nodular melanoma (NM), and acral lentiginous melanoma (ALM). These distinctions are based on the observation that certain combinations of morphological features of the microscopic growth pattern of melanoma during its early progression phase are associated with clinical features such as anatomic site of the primary tumor, pace of tumor evolution, and patient age. Although these proposed categories undoubtedly represent prototypical instances or archetypes of the clinical and histopathological presentations that are valuable for teaching purposes, their impact on clinical management has been limited. A major reason is that no significant difference in overall survival or treatment responses could be demonstrated between the categories when tumors of equivalent tumor thickness were compared or after metastasis had occurred \[[@pmed-0050120-b005]\]. Furthermore, these subtypes are defined by multiple criteria, each assessing complex morphological patterns, resulting in a wide range of possible presentations. Thus a considerable portion of melanomas are differentially classified by multiple observers, or are classified as "ambiguous" \[[@pmed-0050120-b006]\]. Some have questioned the existence of biologically distinct melanoma types altogether, proposing that the morphological differences are entirely secondary to the anatomic site in which the tumor arises \[[@pmed-0050120-b007]\], or, in the case of NM, are a consequence of differences in the pace of tumor evolution \[[@pmed-0050120-b008]\].

In order to establish whether a disease is composed of distinct subtypes it is necessary to integrate clinicopathological features with the underlying biologic factors and identify disease groups that are homogeneous in their etiology, clinical behavior, and management requirements. These subtypes, if found, would then form the basis of a clinically useful classification system. In cancer, genetic alterations can serve as biomarkers for classification purposes, in particular if they are causally linked to the disease process. With the advent of therapeutics targeted to genes and signaling pathways, these oncogenic mutations are gaining direct importance for clinical management. But knowledge of the critical constitutional and somatic genetic factors is currently incomplete. Since the clinical characteristics of a tumor must be, at least in part, genetically determined, elucidation of the phenotypic consequences of currently known genetic factors will reveal aspects of their function and highlight gaps in knowledge, which may guide future discovery. More immediately, clinicopathological features that are associated with specific genetic factors provide an attractive basis on which to build a refined classification system that is practical to implement and useful for patient management.

Recently, we described distinct patterns of chromosomal aberrations and mutations in oncogenes such as *BRAF* and *KIT* that correlated more with the site of the primary tumor and the degree of chronic sun-induced damage of the surrounding skin than with the traditional melanoma types \[[@pmed-0050120-b009]--[@pmed-0050120-b013]\]. Epidemiological studies have independently emphasized the impact of chronic sun exposure on the mole count and survival time of melanoma patients \[[@pmed-0050120-b014],[@pmed-0050120-b015]\]. Together, these findings strongly support the existence of distinct melanoma subtypes, but also indicate that these are insufficiently captured by the existing classification system. Using previously recognized morphological features of primary melanoma, we performed a detailed phenotypic characterization of a large cohort of primary melanomas and correlated those features with the mutation status of *BRAF* and *NRAS*, the most commonly mutated oncogenes known in melanoma. Specifically, we defined simple histomorphologic features that can be reproducibly scored in routinely stained sections.

Methods {#s2}
=======

Tumor Specimens and Mutation Analysis {#s2a}
-------------------------------------

A total of 302 cases of primary cutaneous melanoma that have been part of previous genetic analyses were included in this study \[[@pmed-0050120-b012],[@pmed-0050120-b016]\]. *BRAF* mutation data of exon 15, which includes codon 600, were available from all samples. *NRAS* mutation data of exons 1 and 2 for samples were available from a previously published subset of the samples \[[@pmed-0050120-b012]\], and were obtained for the remainder of the cases using our standard protocols \[[@pmed-0050120-b017]\]. For all cases, *NRAS* was only analyzed in melanomas in which no *BRAF* exon 15 mutations were found because earlier studies indicated a very low rate of cooccurrence of these aberrations.

Histopathological Analysis {#s2b}
--------------------------

All histopathological evaluations were carried out on routinely stained HE sections, processed through the UCSF Dermatopathology Service. Cases were classified into SSM, LMM, NM, and, ALM according to the WHO classification, or not classifiable (NC) if they did not fit unequivocally in any of these categories \[[@pmed-0050120-b002],[@pmed-0050120-b003],[@pmed-0050120-b018]\]. The cases were also classified into acral melanoma, and melanoma arising on skin with or without evidence of chronic sun-induced damage (CSD and non-CSD, respectively), as described previously \[[@pmed-0050120-b012]\].

Analysis of Elementary Histological Features {#s2c}
--------------------------------------------

All sections of tissue that were available for each specimen were examined, and a semiquantitative assessment of each histological feature for a tumor was obtained from the combined analysis of all of the sections. Except where stated otherwise, the morphologic assessments were made in areas of radial growth, excluding areas of vertical growth. Radial growth phase (RGP) and vertical growth phase (VGP) were defined as described by Clark and Elder \[[@pmed-0050120-b019]\]. For melanomas that were classified as NMs in the WHO classification applying the three-rete ridge rule, the assessment was made in any small intraepidermal component adjacent to the nodular portion wherever possible. NMs without a small adjacent intraepidermal component were not assessed for these features. The histological features examined were as follows.

### Upward scatter of intraepidermal melanocytes. {#s2c1}

The proportion of intraepidermal melanocytes present above the basal layer, irrespective of whether suprabasal melanocytes were arranged singly or as nests, was graded from 0 to 3 ([Figure 1](#pmed-0050120-g001){ref-type="fig"}A) using the following criteria: 0, essentially all melanocytes situated at the dermo-epidermal junction, with only rare melanocytes in higher epidermal layers; 1, the majority of melanocytes (75%--100%) situated at the dermo-epidermal junction, with some present in higher epidermal layers; 2, roughly equal proportions of intraepidermal melanocytes present at the dermo-epidermal junction and in higher epidermal layers; 3, most (\>50%) of the intraepidermal melanocytes situated in the upper layers of the epidermis

![Grading of Morphological Features\
(A) Scatter of intraepidermal melanocytes.\
(B) Nesting of intraepidermal melanocytes.\
(C) Cytoplasmic pigmentation of neoplastic melanocytes.\
(D) Cell shapes.](pmed.0050120.g001){#pmed-0050120-g001}

### Nest formation of intraepidermal melanocytes. {#s2c2}

Intraepidermal melanocytes were defined as arranged in nests rather than single cells if they formed clusters of five or more cells no matter where they were located, e.g., whether within the basal epidermis or in higher layers of the epidermis ([Figure 1](#pmed-0050120-g001){ref-type="fig"}B). The degree of nesting was quantified as: 0, intraepidermal melanocytes present almost exclusively as single cells with only rare nests; 1, intraepidermal melanocytes predominantly arranged as single cells with no more than 25% of cells in nests; 2, 25%--50% of the intraepidermal melanocytes in nests; 3, \>50% of the intraepidermal melanocytes in nests.

### Pigmentation of melanocytes. {#s2c3}

Pigmentation was defined as melanin accumulation within the constituent melanocytes and was scored on a five-point scale using 20× and 40× objectives ([Figure 1](#pmed-0050120-g001){ref-type="fig"}C). Melanophages were not considered. Pigmentation was assessed in three different ways: maximum pigmentation anywhere in the tumor; average pigmentation across all sections of the RGP; and average pigmentation across all sections of the vertical growth phase (VGP). These parameters gave similar results in the final analysis ([Table S1](#pmed-0050120-st001){ref-type="supplementary-material"}), so we standardized on using the maximum pigmentation scored anywhere in the tumor. Pigmentation was scored from 0--4 using the scale: 0, (absent) no pigment discernible even at high power; 1, (faint) pigmentation barely visible at low power. At high power, melanocytes showed a faint diffuse melanin pigment or a few pigment granules. 2, (moderate) pigmentation visible at low power with translucent cytoplasm that is significantly lighter than the hematoxylin stained nuclei; 3, (high) pigmentation easily visible at low power with the cytoplasmic pigmentation reaching an intensity approximating that of the nucleus; 4, (very high) cytoplasm strikingly pigmented making it difficult to identify nuclei.

### Epidermal contour. {#s2c4}

The contour of the epidermis involved by the RGP of the melanoma was compared to the adjacent normal epidermis ([Figure S1](#pmed-0050120-sg001){ref-type="supplementary-material"}A) and scored from 0 to 4: 0, (atrophic) markedly thinned epidermis with effacement of rete ridges; 1, (thinned) thinned epidermis with partial attenuation of rete ridges; 2, (normal) epidermal silhouette similar to the adjacent uninvolved epidermis; 3, (thickened) slight to moderate epidermal hyperplasia with elongation of the rete ridges resulting in a maximum 2-fold increase in epidermal thickness; 4, (hyperplastic) marked epidermal hyperplasia resulting in a greater than 2-fold increase in epidermal thickness.

### Lateral circumscription. {#s2c5}

Lateral circumscription was assessed by examining the transition of the intraepidermal growth portion of the tumor to normal skin at the tumor periphery. The area with the most gradual transition in any of the tissue pieces ([Figure S1](#pmed-0050120-sg001){ref-type="supplementary-material"}B) was scored from 0 to 2. 0, (discontinuous) areas of apparently uninvolved epidermis interspersed with tumor. Areas of uninvolved epidermis apparently caused by regression were considered tumor; 1, (gradual but continuous) continuous decrease of the number of intraepidermal melanocytes making it difficult to pinpoint the transition to normal skin to within one or two rete ridges or 0.1 mm; 2, (abrupt) transition from involved epidermis to the adjacent normal skin easily determined within one or two rete ridges or 0.1 mm.

### Solar elastosis. {#s2c6}

The degree of solar elastosis was classified on an 11-category scale ranging from 0 to 3+ by examining the normal skin surrounding the melanoma using the 10× and 20× lenses, as described previously \[[@pmed-0050120-b016]\].

### Size and shape of cells, nuclei, and nucleoli. {#s2c7}

Size and shape of tumor cells and their nuclei were assessed in the most cellular portion of the tumor using a 20× lens. Nuclei of small lymphocytes, which we determined ranged in size from 4 to 5 μm, were used as a size reference. Visual assessment of size was quantified on a scale from 1 to 3. Tumor cells were considered 1, small; 2, medium; or 3, large, if the greatest diameter was \<8 μm, between 8 and 10 μm, and \>10 μm, respectively ([Figure S1](#pmed-0050120-sg001){ref-type="supplementary-material"}C). Similarly, nuclei were considered 1, small; 2, medium; and 3, large, if the greatest diameter was \<5 μm, between 5 and 6 μm, and \>6 μm. Nucleolar size was assessed in the most cellular portion of the tumor using a 40× lens: 1, (small) nucleoli of tumor cells smaller than those of keratinocytes, or not discernible; 2, (medium) tumor nucleoli comparable in size to those of keratinocytes; 3, (large) tumor nucleoli larger than those of keratinocytes.

Cell shape was visually assessed at 20× in the most cellular portion of the tumor using ([Figure 1](#pmed-0050120-g001){ref-type="fig"}D). The visual assessment graded the cells from 0 to 3: 0, (round) long and short diameters approximately equal; 1, (ovoid) long diameter approximately one-third greater than the short diameter; 2, (elongated) long diameter between one-third and two times longer than the short diameter; 3, (spindled) long diameter \>two times the short diameter.

Sizes and shapes of cells were also determined quantitatively in 264 samples of the cohort using photomicrographs taken with a 20× lens and averaging ten random cells within a representative area ([Table S2](#pmed-0050120-st002){ref-type="supplementary-material"}). Sizes were expressed as the product of the long and short diameter (μ^2^), and shapes as their ratio. Quantitative and visual measurements showed good agreement (Kendall\'s Tau Test 0.4--0.6) ([Table S3](#pmed-0050120-st003){ref-type="supplementary-material"}). The visual assessments were used in the analysis, as discussed below.

### Ulceration. {#s2c8}

Ulceration was defined as the presence of a full-thickness epidermal defect; evidence of host response (i.e., fibrin deposition, neutrophils); and thinning, effacement, or reactive hyperplasia of the surrounding epidermis \[[@pmed-0050120-b020]\].

### Thickness. {#s2c9}

Tumor thickness was measured in millimeters according to Breslow \[[@pmed-0050120-b021]\].

Statistical Analysis {#s2d}
--------------------

The univariate analyses for binary outcomes (e.g., *BRAF* mutation present or not) were performed by fitting a logistic regression with each of the measurements. Standard error of the odds ratio (OR) was determined using the Taylor expansion rule. All ordinal measurements of the phenotypic characteristics were treated as scores in the analyses after testing for linearity of the scores with respect to each outcome. Where nonlinear, the polynomials of higher order were fitted to correct nonlinearity according to the default approach to treatment of ordinal variables. Continuous variables (thickness, cell size, cell shape, nuclear size, and nuclear shape) were preprocessed by adding one-tenth of the smallest nonzero value of the respective variable followed by taking log10 of the values to render their distribution more normal. The unordered categorical variables (anatomic site, WHO type, non-CSD, CSD, Acral grouping \[[@pmed-0050120-b011]\], and gender) were treated as factor variables in logistic regression. Multivariate analyses to predict mutation status were performed using single binary classification tree classifiers \[[@pmed-0050120-b022]\], Random Forests \[[@pmed-0050120-b023]\], and multivariate logistic regression. A detailed description of the methods is provided in the [Text S1](#pmed-0050120-sd002){ref-type="supplementary-material"}. All statistical analyses were conducted using the freely available R statistical language.

Results {#s3}
=======

Morphometric Analysis of Phenotypic Features {#s3a}
--------------------------------------------

Clinical information, *BRAF* mutation status, and WHO classifications of all 302 primary cutaneous melanomas in this study are summarized in [Table 1](#pmed-0050120-t001){ref-type="table"}. The phenotypic characteristics that we focused on in our measurements comprised "elementary" features that mostly are combined in various ways in the WHO classification. For example, in the WHO classification the features "lentiginous" and "pagetoid" growth are prominently used as opposing ends of a spectrum of intraepidermal growth. However, both lentiginous and pagetoid are "complex" patterns composed of several separable features including (a) whether the neoplastic melanocytes are scattered throughout all layers of the epidermis (in pagetoid) or are situated in the basal layer (in lentiginous); (b) whether the cells are arranged partially in nests (in pagetoid) or predominantly as single units (in lentiginous); and (c) whether the melanocytes are enlarged and round (in pagetoid) or small with scalloped contours or spindled (in lentiginous). Therefore to describe intraepidermal growth we defined and assessed features termed: scatter, nest formation, size and shape ([Figure 1](#pmed-0050120-g001){ref-type="fig"}). Similar to the WHO classification, we focused our evaluation of the features primarily on the early progression phases, e.g., the RGP of the tumor in the expectation that this would be the most informative regarding its "histogenetic" origin.

###### 

Clinical Characteristics of Patients and Melanomas by Mutation Status of *BRAF* and *NRAS* Included in Our Analysis

![](pmed.0050120.t001)

All features were visually scored in the 302 tumors by one of us (AV). Interobserver agreement was determined by having an additional observer (JB) score a randomly selected subset of 50 cases. The scorers were blinded to knowledge of the genetic status of the tumors until the scoring was complete. Kappa statistics \[[@pmed-0050120-b024]\] indicated moderate to excellent agreement ([Table S4](#pmed-0050120-st004){ref-type="supplementary-material"}). [Table 2](#pmed-0050120-t002){ref-type="table"} shows the number of tumors by phenotypic feature and mutation status. [Figure 2](#pmed-0050120-g002){ref-type="fig"} shows a heatmap of features by mutation status ([Figure 2](#pmed-0050120-g002){ref-type="fig"}A) and by the WHO subtypes ([Figure 2](#pmed-0050120-g002){ref-type="fig"}B).

###### 

Morphologic Features of Melanomas by Mutation Status of *BRAF* and *NRAS* Included in Our Analysis

![](pmed.0050120.t002)

![Heatmap of Features by Mutation Status (A) and by WHO Subtypes (B)\
Variables significantly associated with *BRAF*. Samples are in columns, variables in rows. The scores range from shades of blue (low score), to gray (intermediate scores), to yellow (high scores). Samples are ordered within each category using agglomerative hierarchical clustering on morphological variables by Euclidean distance and Ward\'s criterion. Ac, acral; CSD, chronic sun damage as defined in \[[@pmed-0050120-b012]\]; H, head; LE, lower extremity; Tr, trunk; UE, upper extremity;.](pmed.0050120.g002){#pmed-0050120-g002}

*BRAF*, but Not *NRAS*, Mutation Status Is Strongly Related to Some Phenotypic Features {#s3b}
---------------------------------------------------------------------------------------

[Tables 3](#pmed-0050120-t003){ref-type="table"} and [S5](#pmed-0050120-st005){ref-type="supplementary-material"} show the results of univariate analysis to determine the association statistic between the elementary phenotypes and mutation status. Several are highly significant. Since most of the features are assessed as ordinal variables, the ORs reflect the increase (or decrease) of the odds per unit increment. For example in the comparison of nesting between melanomas with and without *BRAF* mutations (first column), the OR of 3.11 indicates the increase in odds for one increment of the ordinal scale for scatter (e.g., nesting 1 to nesting 2). To calculate the odds for an increment of two the indicated OR should be squared. Compared to melanomas without *BRAF* mutations, melanomas with *BRAF* mutations showed statistically significantly higher degrees of intraepidermal scatter of melanocytes, and a higher proportion of melanocytes arranged in nests. In addition, the epidermis of the RGP of melanomas with *BRAF* mutations was more commonly thickened compared to the surrounding skin, i.e., the score for the "epidermal contour" had a higher average value, and the transition from the tumor into the surrounding skin tended to be more abrupt than in melanomas without *BRAF* mutations, i.e., "lateral circumscription" had a higher average score. Furthermore, the tumor cells of *BRAF*-mutated melanomas were larger, had a rounder shape, and showed a higher degree of pigmentation than cells in tumors without *BRAF* mutations. As we reported previously \[[@pmed-0050120-b016]\], melanomas with *BRAF* mutations also had a lower degree of solar elastosis in the surrounding skin than melanomas without *BRAF* mutations.

###### 

Comparison of Morphological Variables Depending on the Mutation Status of *BRAF* and *NRAS*

![](pmed.0050120.t003)

Given the significant univariate correlations, we employed several multivariate statistical approaches to define the most powerful combinations of variables for prediction of mutation status. These analyses produced a consistent set of variables that included the morphological features pigmentation, upward scatter, nesting of intraepidermal melanocytes, and cell shape. In addition, a younger age at diagnosis was independently associated with *BRAF* mutation status ([Table S6](#pmed-0050120-st006){ref-type="supplementary-material"}). The results of the multivariate analyses are most intuitively displayed using a binary classification tree since it defines a decision structure using specific thresholds for individual characteristics at each node. Classification trees developed using all clinical and morphologic variables correctly predicted *BRAF* mutation status with up to 82% accuracy if one required a prediction for all tumors. Classification trees with high prediction accuracy also formed when only morphologic features were included in the model. [Figure 3](#pmed-0050120-g003){ref-type="fig"}A shows one such tree, which has 76% accuracy for predictions for all samples. However, it is clear that some branches of the tree lead to much stronger predictions than others. Thus tumors without "upward scatter" have a very low probability of being *BRAF* mutant, while those with "scatter" \> 0 and "nesting" \> 2 are almost all *BRAF* mutant. However, tumors with "scatter" \> 0 but lower "nesting" have about equal chance of being *BRAF* wild-type (47%) or mutant (53%), with high "pigmentation" increasing the odds of being mutant to 70%.

![Prediction Algorithms of *BRAF* Mutation\
Prediction trees for *BRAF* mutation status with morphologic variables (A) or variables in the Southern German Tumor Registry (B).\
(A) Terminal nodes display heatmaps showing samples by mutation status, ordered and coded as in [Figure 2](#pmed-0050120-g002){ref-type="fig"}A.\
(B) The prediction tree for *BRAF* mutation using the variables of age, sex, body site, and WHO type also recorded in melanoma registries identifies an age cutoff of 55 y as the single best predictor of *BRAF* mutation status. Kaplan Meier survival analysis from the Southern German Tumor Registry shows a significant (*p* \< 0.0001) decrease in survival when stratified by this age cutoff.](pmed.0050120.g003){#pmed-0050120-g003}

Although intuitive to interpret, single classification trees are inherently unstable in the sense that slight perturbations in the dataset used for tree building may lead to large changes in the tree topology, e.g., several trees with approximately the same discrimination power can be found. Resampling-based algorithms are well-known solutions for improving the accuracy of single classification trees. We used the Random Forest classifier, a method that grows many classification trees, each based on a different subset containing on average 66% of the samples. The resulting collection of individual trees is referred to as "random forest." The final prediction for each sample is the outcome of the majority vote of those trees in the forest that did not include that sample in their development. The unbiased estimate of the error is given by 1, prediction accuracy \[[@pmed-0050120-b023],[@pmed-0050120-b025]\]. As expected, random forests significantly improved the classification performance, correctly predicting *BRAF* status with 91.8% accuracy using all variables, and 87% using morphological variables only. In comparison, the probability for predicting *BRAF* mutation in this dataset by chance is about 50%. Thus the conventional morphological parameters of a tumor are substantially affected by *BRAF* mutations. The performances of the different classification approaches we applied are summarized in [Table S6](#pmed-0050120-st006){ref-type="supplementary-material"}.

While the elementary morphological characteristics that contribute to the WHO classification system have a very strong relationship to *BRAF* mutation status, the WHO categories were not independently associated with *BRAF* mutation status since mutations are found in considerable proportions of all WHO categories, with the exception of ALM, [Table 1](#pmed-0050120-t001){ref-type="table"}, and [Figure 2](#pmed-0050120-g002){ref-type="fig"}. The strong relationship of the elementary characteristics to mutation status is emphasized by the fact that the same associations remained significant when the analyses were restricted to individual WHO categories, where the proportion of mutations ranged from 13% in the Acral category to 52% in the SSM category ([Table S7](#pmed-0050120-st007){ref-type="supplementary-material"}). These findings suggest that the elementary features can be combined to a refined classification algorithm yielding melanoma groups that are more homogeneous with regard to their underlying genetic alterations.

In contrast to *BRAF*, a different, much smaller, set of significant criteria was found in univariate comparisons between melanomas with *NRAS* mutations and melanomas with mutations in neither *BRAF* nor *NRAS* ([Tables 3](#pmed-0050120-t003){ref-type="table"} and [S2](#pmed-0050120-st002){ref-type="supplementary-material"}). However, the single tree classifier did not produce any significant splits indicating that the power of these variables to predict *NRAS* mutation status was limited.

We did not have sufficient outcome information of the patients in our cohort to test for differences between the melanoma groups formed by the classification tree of [Figure 3](#pmed-0050120-g003){ref-type="fig"}A. Since none of the morphological features assessed in our study is currently recorded in any tumor registry we also could not readily apply this approach to existing clinical cohorts. However, gender, patient age, WHO subtype, site of primary tumor, tumor thickness, and presence or absence of ulceration are routinely recorded in registries. Using these variables only on our data, a classification tree consisting of a stump (a tree with only two terminal nodes) was formed with age as the sole criterion for predicting *BRAF* status. Using this tree 69% of the melanomas in patients under the age of 55 y had *BRAF* mutant tumors, while only 35.3 % were *BRAF* mutant in older patients ([Figure 3](#pmed-0050120-g003){ref-type="fig"}B). Applying this age cutoff to a cohort of 4,785 patients from the German Melanoma Registry \[[@pmed-0050120-b026]\] significant differences in disease-specific overall survival and disease-free survival were found ([Figure 3](#pmed-0050120-g003){ref-type="fig"}B). In multivariate analysis, this age cutoff was associated with outcome independent of tumor thickness, anatomic site, and presence or absence of ulceration. In addition to a better prognosis, the group that, on the basis of their age, was more likely to have a *BRAF* mutant melanoma more frequently presented with metastases to regional nodes; whereas patients that, on the basis of their age, were less likely to have a *BRAF* mutant melanoma tended to have either localized or systemic metastases ([Table S8](#pmed-0050120-st008){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In this study we demonstrate that histopathological features of the primary tumor, many of which have been part of the WHO classification, provide substantial information on the mutation status of an important melanoma gene, *BRAF*. We found that phenotypic features such as increased upward scatter and nest formation of intraepidermal melanocytes; thickening of the involved epidermis; sharp demarcation from the surrounding skin; as well as the presence of a larger, rounder, and more pigmented tumor cells were distinguishing features of melanomas with *BRAF* mutation. This finding suggests that further research will reveal additional phenotypic associations with other genetic factors, including both germ line constitution of the patient and the somatic alterations in the tumor. In general it is not to be expected that single morphological parameters will be associated with individual genetic factors since it is likely that there will be interactions, or partial or functional redundancy, among them.

Results of genotype-phenotype studies can be applied in two directions. Starting with the genetics, the resulting phenotypes may allow generation of hypotheses concerning the function of a genetic factor. For example, our observation of increased melanin pigment in the tumor cells in melanomas with *BRAF* mutations is in line with recent reports of cooperation between *BRAF* and MITF in melanoma development. MITF is an important transcriptional regulator of pigmentation that is amplified in a subset of melanomas and cooperates with *BRAF* in transforming immortalized human melanocytes \[[@pmed-0050120-b027]\]. A link between *BRAF* and pigmentation is further supported by a recent independent observation that *BRAF*-mutant melanomas are also more pigmented macroscopically \[[@pmed-0050120-b028]\]. Our study also identified strong associations between upward scatter of intraepidermal melanocytes and formation of nests and *BRAF* mutation. Upward scatter is unlikely to be entirely attributable to *BRAF* mutations, as scatter is typically absent in nevi, many of which have *BRAF* mutations \[[@pmed-0050120-b029]\], suggesting that other genes cooperating with *BRAF* may be involved. By contrast, many nevi also show melanocytes arranged in nests and are sharply circumscribed, features that are also more frequent in *BRAF*-mutant melanomas. Studies to determine which of the features found here to be associated with *BRAF* mutant melanomas show similar genotype-phenotype associations in nevi are currently underway.

In the other direction, phenotypic characteristics that are conventionally assessed in the clinic can be used to develop a practical classification system in which the classes are genetically homogeneous, and thus more likely to provide information relevant to patient management. Such a system may provide valuable, outcome-related information from its classes even before the genetic factors of each class are completely understood. Such a classification system is likely to have an important clinical impact. To achieve this goal the practicability and interobserver reproducibility of the criteria that we defined need to be assessed in a clinical setting and the classification algorithms validated on independent cohorts of cases. Such efforts have been initiated and shown good to excellent interobserver agreements in scoring the features used in this study among expert pathologists (to be published separately).

Among the few variables in our study that overlapped with data recorded in large patient registries, age was the variable that best predicted *BRAF* status. A strong association between patient age at diagnosis and *BRAF* mutation status has been reported previously by us and others \[[@pmed-0050120-b011],[@pmed-0050120-b028],[@pmed-0050120-b030],[@pmed-0050120-b031]\]. Using the age cutoff of 55 y determined in our experimental cohort, we found a significant difference in disease-specific and relapse-free (unpublished data) survival in an independent clinical cohort of 4,785 patients. Several previous studies including our own \[[@pmed-0050120-b011],[@pmed-0050120-b030],[@pmed-0050120-b032]--[@pmed-0050120-b036]\] have not found significant survival differences between melanomas with and without *BRAF* mutation. However, the numbers of patients in these studies are comparably small, and this simple cutoff may be reflecting currently unknown genetic effects that interact with or substitute for *BRAF* mutations, and thus reveal significantly different clinical behavior. Future studies will be required to better understand the factors involved in this survival difference, hopefully resulting in improved ability to predict the future course of a particular tumor.

The presence of *NRAS* mutations was not strongly associated with the phenotypic measurements we performed. In the univariate analysis the majority of the OR point estimates for association with *NRAS* mutation are close to one, and so if true associations are present we would expect them to be much weaker than for *BRAF*. Multivariate analyses did not significantly enhance the prediction power. This dissimilarity could reflect differences in signaling between *BRAF* and *NRAS*, with *NRAS* having more pleiotropic effects. Larger numbers of cases and additional knowledge of equivalent genetic alterations in melanomas without *BRAF* and *NRAS* mutations are required to evaluate whether some of the features used here and/or others can further increase the discrimination between genetically defined subtypes. We have recently described activation of KIT by mutation and/or copy number increases in mucosal, acral, and CSD melanomas \[[@pmed-0050120-b013]\]. Too little tissue or DNA was left from the current cohort of cases to test for associations between KIT aberrations and any of our features.

Disease classification evolves from descriptions of a combination of symptoms (syndromes), to more refined definitions that integrate underlying causes. The increase in knowledge of underlying causative genetic alterations in melanoma offers an opportunity to reassess the syndromic classification scheme that emerged from the Sydney classification \[[@pmed-0050120-b003]\] and its revision \[[@pmed-0050120-b004]\] into the current WHO classification. The genotype-phenotype correlations discovered in our study testify to the intuition of the originators of the morphological classification scheme. The observation that simple combinations of features could predict *BRAF* mutation status independent of, and even within WHO subtypes, indicates that the morphological criteria we used can be employed to refine the existing classification, providing an opportunity to identify disease subsets that are genetically more homogenous. Our result represents but one step towards improved classification, and we expect it to be modified in light of future discoveries.

In the distant future when genetic knowledge is complete and targeted therapeutic options are numerous, the appropriate clinical work up of a patient is likely to be quite different from current practice. While initial diagnosis and aspects of staging will require histopathology, more subtle distinctions will employ molecular analysis. Reaching this goal requires following a complex, uncertain path of incremental advances built on new discoveries and continuous refinement of perceived relationships among disparate types of knowledge. Here we have investigated the relationship of elementary histopathological characteristics of melanomas to the mutation status of two genes, *BRAF* and *NRAS*. A strong relationship was found for the first but not for the second. As more studies are performed, additional strong genotype-phenotype relationships may be found, more subtle effects of genetic interactions and complementation may be revealed, and consequences of these factors for clinical behavior of individual tumors may be elucidated. As this process unfolds, phenotypic characteristics will become progressively more useful as surrogates for missing genetic knowledge. Thus development of a melanoma classification system that combines analysis of known genetic factors with histopathology may produce a clinically powerful method for managing individual patients and guiding research in the immediate future.
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\(A\) Epidermal contour, (B) lateral circumscription of tumors, (C) cell size.
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The data are shown by mutation status of *BRAF* and *NRAS*. The variable of maximum pigmentation was used for statistical analysis and is shown in [Tables 1](#pmed-0050120-t001){ref-type="table"}--[3](#pmed-0050120-t003){ref-type="table"}. Total percentages that do not add up to 100% have missing values.
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###### Quadratic Weighted Kappa Coefficient Reflecting Interobserver Agreement between Two Observers Assessed on 50 Samples

(27 KB DOC)

###### 

Click here for additional data file.

###### Alternative Assessments

Alternative assessments of pigmentation as well as morphometric assessments of cellular and nuclear sizes and shapes show similar associations with the mutation status of *BRAF* and *NRAS* than variables used in the main analysis ([Tables 2](#pmed-0050120-t002){ref-type="table"} and [3](#pmed-0050120-t003){ref-type="table"}). For ordinal variables the OR is displayed as mean OR per incremental unit. CI is confidence interval.

(34 KB DOC)

###### 

Click here for additional data file.

###### Proportion of Misclassified Cases Using Different Statistical Procedures Using Four Binary Predictions with All (Morphological and Demographic) Variables

Base prediction rate (defined as proportion of the minority class) were 47, 26, 44, and 31% for the entire cohort in each of the four pair-wise comparisons, respectively. Multivariate Logistic Regressions were fit with the variables selected using the single tree (tree) and using the Bayesian information criterion (BIC). The misclassification rate is shown for the entire cohort as well as for samples for which none of the variables are missing. For methods that allow extraction of the independently associated variables those that were found to be significant are shown in the final column.

(59 KB DOC)

###### 

Click here for additional data file.

###### Comparison of Features within SSMs by Mutation Status of *BRAF* and *NRAS*

Total percentages that do not add up to 100% have missing values.

(125 KB DOC)

###### 

Click here for additional data file.

###### First Metastasis Site

Site of first metastasis in patients who are older and younger than 55 y of age recorded in the Southern German Tumor Registry, with Chi-squared *p*-value analysis showing a significant (\<0.0001) difference.

(29 KB DOC)

###### 

Click here for additional data file.

###### Detailed Methods for Classification Approaches

(29 KB DOC)

###### 

Click here for additional data file.

ALM

:   acral lentiginous melanoma

CSD

:   chronic sun-induced damage

LMM

:   lentigo maligna melanoma

NC

:   not classifiable

NM

:   nodular melanoma

OR

:   odds ratio

RGP

:   radial growth phase

SSM

:   superficial spreading melanoma

WHO

:   World Health Organization
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